Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | DHFR | P00374 | 2/20 | 0.33 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | ATR | Q13535 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18657377 | 0.80 | DHFR (0.33) | HRH4HRH3KCNH2DHFRMAPKAPK2 | |
| SCHEMBL84356 | 0.80 | NOS3 (0.40) | DHFRP2RX3P2RX2 | |
| SCHEMBL14864222 | 0.79 | TBK1 (0.40) | DHFRMAPKAPK2P2RX3P2RX2 | |
| SCHEMBL20125018 | 0.77 | NOS3 (0.50) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL20801904 | 0.76 | CYP1A2 (0.43) | SLC6A2SLC6A4SLC6A3DHFRATR | |
| SCHEMBL1093855 | 0.75 | KMT2A (0.48) | SLC6A2SLC6A4HRH3KCNH2NPC1 | |
| SCHEMBL20801738 | 0.75 | DHFR (0.30) | DHFR | |
| SCHEMBL15828598 | 0.72 | DHFR (0.33) | SLC6A2SLC6A4SLC6A3KCNH2DHFR | |
| SCHEMBL15471948 | 0.71 | HTT (0.42) | HRH4HRH3KCNH2DHFRMAPKAPK2 | |
| SCHEMBL84407 | 0.70 | NOS3 (0.56) | HRH4HRH3KCNH2DHFRP2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210032207-A1 | QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210032207-A1 | QUINOLONE COMPOUND | HAX1, NQO2, CXCR1 | SLC6A2 1442/4885SLC6A4 796/4885SLC6A3 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.